December 29, 2025 08:03 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Supreme Court puts Aravalli redefinition on hold amid uproar, awaits new expert committee | Supreme Court strikes! Kuldeep Sengar’s bail in Unnao case suspended amid public outcry | From bitter split to big reunion! Pawars join hands again for high-stakes civic battle | CBI moves Supreme Court challenging Kuldeep Sengar's relief in Unnao rape case | Music under attack: Islamist mob attacks James concert with bricks, stones in Bangladesh, dozens hurt | Christmas vandalism sparks mass arrests in Raipur; Assam acts too with crackdown on 'religious intolerance' | BJP's VV Rajesh becomes Thiruvananthapuram Mayor after party topples Left's 45-year-rule in city corporation | ‘I can’t bear the pain’: Indian-origin father of three dies after 8-hour hospital wait in Canada hospital | Janhvi Kapoor, Kajal Aggarwal, Jaya Prada slam brutal lynching in Bangladesh, call out ‘selective outrage’ | Tarique Rahman returns to Bangladesh after 17 years

Two Aurobindo Pharma products receive USFDA approval

| | Apr 01, 2016, at 08:19 pm
Hyderabad/Mumbai, Apr 1 (IBNS) Aurobindo Pharma Limited announced on Friday that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valganciclovir Tablets USP, 450 mg; and Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial.
The company said that the Valganciclovir Tablet is to be launched in Q1 FY16-17 and the Vancomycin Hydrochloride for Injection in the later part of the same fiscal year.
 
Valganciclovir tablets is an anti-viral used in the treatment of Cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome and prevention of CMV disease in kidney, heart or kidney-pancreas transplant patients.
 
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Valcyte of Hoffman-La Roche Inc.
 
The approved product has an estimated market size of US$ 391 million for the12 months ending February 2016 according to IMS.
 
Vancomycin Hydrochloride for Injection is an antibiotic used in the treatment of severe infections caused by susceptible strains of methicillin-resistant (Beta-lactam resistant) staphylococci and others. The approved product has an estimated market size of US$ 94 million for the twelve months ending January 2016 according
to IMS.
 
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Vancomycin® Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, of Fresenius Kabi USA, LLC. 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm